Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available
Open Access
- 18 July 2019
- journal article
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 12 (2)
Abstract
No abstract availableThis publication has 2 references indexed in Scilit:
- Biosimilar and generic cancer drugs unlikely to bend cost curve in the USAThe Lancet Oncology, 2017
- Validation of predictive pharmacoeconomic model of introduction of medicinal product ibrutinib into chronic lymphatic leukemia therapy practice in the territory of the Russian FederationPharmacoeconomics: theory and practice, 2015